Marion Dorsch, Ph.D.Chief Scientific Officer at Blueprint Medicines
Marion has over 20 years of experience in the biopharmaceutical industry with a strong track record of discovering and advancing innovative therapies to patients. She joined Blueprint Medicines from Agios Pharmaceuticals, Inc. where she served as Vice President of Biology and was responsible for novel target validation, drug discovery, and biomarker strategy across Agios’ cancer, rare genetic diseases and immuno-oncology portfolios. During her tenure at Agios, Marion contributed to the successful advancement of several molecules targeting defined genetic lesions into clinical trials, two of which were recently approved in relapsed/refractory AML. Prior to joining Agios, Marion was the Director of Cancer Biology at Sanofi Oncology, where she oversaw drug discovery efforts. Earlier in her career, Marion served as research project leader for sonidegib (Odomzo), now approved in the U.S. and EU for the treatment of locally advanced basal cell carcinoma, at the Novartis Institutes for Biomedical Research and also worked in Inflammation Discovery at Millennium Pharmaceuticals. Marion received her Ph.D. in Biology from the Free University of Berlin, Germany and was a postdoctoral fellow at Columbia University in New York.